Drug intelligence / Profile preview

AVTX-010

Development stage: Preclinical
Lead developer: Avalo Therapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

AVTX-010 is a long-acting, next-generation monoclonal antibody that targets interleukin-1 beta (IL-1β). Developed by Avalo Therapeutics, it is designed to build upon the clinical profile of abdakibart (AVTX-009). The asset is intended for the treatment of inflammatory diseases, with a primary focus on Hidradenitis Suppurativa (HS). By neutralizing IL-1β, a key pro-inflammatory cytokine, AVTX-010 aims to inhibit the inflammatory cascade responsible for the painful nodules and abscesses characteristic of HS. Its long-acting properties are intended to provide a more convenient dosing schedule compared to first-generation anti-IL-1β therapies.

Targets

IL1B (Interleukin-1 beta)

Beyond the preview

Go deeper on AVTX-010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVTX-010.

Explore the full profile